These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 18549914)

  • 1. Pharmacologic strategies to target oxidative stress in heart failure.
    Ahmed Z; Tang WH
    Curr Heart Fail Rep; 2012 Mar; 9(1):14-22. PubMed ID: 22213193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular proliferative response to cardiac troponin-I in patients with idiopathic dilated cardiomyopathy.
    Lappé JM; Pelfrey CM; Cotleur A; Tang WH
    Clin Transl Sci; 2011 Oct; 4(5):317-22. PubMed ID: 22029801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
    Hare JM; Mangal B; Brown J; Fisher C; Freudenberger R; Colucci WS; Mann DL; Liu P; Givertz MM; Schwarz RP;
    J Am Coll Cardiol; 2008 Jun; 51(24):2301-9. PubMed ID: 18549913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study.
    Cingolani HE; Plastino JA; Escudero EM; Mangal B; Brown J; Pérez NG
    J Card Fail; 2006 Sep; 12(7):491-8. PubMed ID: 16952781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservation of cardiac contractility after long-term therapy with oxypurinol in post-ischemic heart failure in mice.
    Tan Z; Dai T; Zhong X; Tian Y; Leppo MK; Gao WD
    Eur J Pharmacol; 2009 Oct; 621(1-3):71-7. PubMed ID: 19737552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xanthine oxidase inhibitors: an emerging class of drugs for heart failure.
    Kittleson MM; Hare JM
    Eur Heart J; 2005 Aug; 26(15):1458-60. PubMed ID: 15917281
    [No Abstract]   [Full Text] [Related]  

  • 8. The ongoing search for a stratified medicine approach in heart failure.
    Tang WH
    J Am Coll Cardiol; 2008 Jun; 51(24):2310-2. PubMed ID: 18549914
    [No Abstract]   [Full Text] [Related]  

  • 9. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
    Harzand A; Tamariz L; Hare JM
    Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of urate and xanthine oxidase inhibitors in cardiovascular disease.
    George J; Struthers AD
    Cardiovasc Ther; 2008; 26(1):59-64. PubMed ID: 18466421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uric acid in chronic heart failure.
    Doehner W; Anker SD
    Semin Nephrol; 2005 Jan; 25(1):61-6. PubMed ID: 15660337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The year in heart failure.
    Tang WH; Francis GS
    J Am Coll Cardiol; 2005 Dec; 46(11):2125-33. PubMed ID: 16325052
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.